Jazz Pharmaceuticals plc Share Price Today: Live Updates & Key Insights
Jazz Pharmaceuticals plc share price today is $180.62, up -0.65%. The stock opened at $182.69 against the previous close of $181.8, with an intraday high of $183.47 and low of $179.1575.
Jazz Pharmaceuticals plc Share Price Chart
Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc Share Price Performance
Jazz Pharmaceuticals plc Institutional Holdings
Jazz Pharmaceuticals plc Market Status
Jazz Pharmaceuticals plc Fundamentals
Market Cap 11119.03 M
PB Ratio 2.5748
PE Ratio 0.0
Enterprise Value 14101.61 M
Total Assets 11659.34 M
Volume 1076791
Jazz Pharmaceuticals plc Company Financials
About Jazz Pharmaceuticals plc & investment objective
Company Information Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Organisation Biotechnology
Employees 2890
Industry Biotechnology
CEO Ms. Renee D. Gala
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
Jazz Pharmaceuticals plc FAQs
What is the share price of Jazz Pharmaceuticals plc today?
The current share price of Jazz Pharmaceuticals plc is $180.62.
Can I buy Jazz Pharmaceuticals plc shares in India?
Yes, Indian investors can buy Jazz Pharmaceuticals plc shares by opening an international trading and demat account with Motilal Oswal.
How to buy Jazz Pharmaceuticals plc shares in India?
You can easily invest in Jazz Pharmaceuticals plc shares from India by:
- Direct Investment:
Opening an international trading account with Motilal Oswal which includes KYC verification in the US. Your account gets activated in a few minutes to a few hours, after which you can start adding funds in USD balance to buy Jazz Pharmaceuticals plc shares. - Indirect Investment:
Under this form of investment, you can choose either a Mutual Fund (MF) or an Exchange-Traded Fund (ETF) that invests in global shares and start investing in shares of Jazz Pharmaceuticals plc.
Can I buy fractional shares of Jazz Pharmaceuticals plc?
Yes, many platforms allow you to buy fractional shares starting from as low as $1.
What is the market capitalization value of Jazz Pharmaceuticals plc?
Jazz Pharmaceuticals plc has a market cap of $11119.03 M.
In which sector does Jazz Pharmaceuticals plc belong?
Jazz Pharmaceuticals plc operates in the Biotechnology sector.
What documents are required to invest in Jazz Pharmaceuticals plc stocks?
To invest, you typically need:
What is the PE and PB ratio of Jazz Pharmaceuticals plc?
The PE ratio of Jazz Pharmaceuticals plc is N/A and the PB ratio is 2.57.